Dec 29 (Reuters) - Ultragenyx Pharmaceutical (RARE.O), opens new tab said on Monday that late-stage studies showed its drug for a type of genetic bone disease failed to reduce the number of fractures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results